Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Hello David- I read your story on your website. I’d like to say congratulations and I wish I could shake your hand and hug you on your story and your victory over multiple myeloma.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Let me know if you have any questions.
Stanislaw Burzynski
Burzynski graduated from the Medical Academy in Lublin[1][2] earning a Ph.D. in biochemistry.[3]
Burzynski moved to the United States in 1970, working at Baylor College until 1977, when he established the Burzynski Research Laboratory where he administered antineoplaston therapy, initially to 21 patients but then more widely as “experimental” treatment. This opened him up to “charges of unethical conduct and to the suspicion he had become a merchant of false hope”, which led to several instances of media controversy.[1]:138
Burzynski founded the Burzynski Research Institute in 1984.[4] His scientific papers have caused academic controversy, with reviewers disputing the design of the trials and scientific validity of the published results.[5][6][7]
In February 2017 following lengthy hearings the Texas Medical Board recommended Burzynski’s medical license be revoked, with the revocation suspended, and a fine of $360,000 for billing irregularities and other violations.[8]
Antineoplaston therapy
Antineoplaston is a name coined by Burzynski for a group of peptides, peptide derivatives, and mixtures that he uses as an alternative cancer treatment.[9] The word is derived from neoplasm.[10]
Antineoplaston therapy has been offered in the U.S. since 1984 but is not approved for general use. The compounds are not licensed as drugs but are instead sold and administered as part of clinical trials at the Burzynski Clinic and the Burzynski Research Institute.[11][12][13]
Burzynski stated that he began investigating the use of antineoplastons after detecting what he considered significant differences in the presence of peptides between the blood of cancer patients and a control group.[14] He first identified antineoplastons from human blood. Since similar peptides had been isolated from urine, early batches of Burzynski’s treatment were isolated from urine.[14] Burzynski has since produced the compounds synthetically.[15]
The first active peptide fraction identified was called antineoplaston A-10 (3-phenylacetylamino-2,6-piperidinedione). From A-10, antineoplaston AS2-1 was derived – a 4:1 mixture of phenylacetic acid and phenylacetylglutamine.[16] The Burzynski Clinic website states that the active ingredient of antineoplaston A10-I is phenylacetylglutamine.[13]
Since 2011, the clinic has marketed itself as offering “personalized gene-targeted cancer therapy”, which has stirred further controversy, as the treatment bears no relationship to gene-targeted therapy and only superficially incorporates elements of personalized medicine.[17] The clinic’s version of personalized medicine bears little resemblance to targeted cancer therapy, as the clinic includes chemotherapy drugs and antineoplastons are part of this treatment.[18][19]